This review explored a range of novel therapies for AD, including anti-TSLP, anti-IL-1α, anti-IL-33, anti-IL-36R, anti-IL-12/IL-23, anti-IL-23, and anti-IL-17, as well as histamine receptor antagonists and NK-1 receptor antagonists. Here, IL23A is linked to Alzheimer disease.